• Citer

An ongoing European organization for research and treatment of cancer crossover trial comparing single-agent paclitaxel and doxorubicin as first- and second-line treatment of advanced breast cancer.

par Piccart-Gebhart, Martine ;Bruning, Peter;Gamucci, T;Klijn, J G;Roy, J A;Awada, Ahmad ;Kusenda, Zlatko;Van Vreckem, Ann;Paridaens, R.
Référence Seminars in oncology, 23, 5 Suppl 11, page (11-15)
Publication Publié, 1996-10

Article révisé par les pairs

• Détails
• Contenu

Titre:	An ongoing European organization for research and treatment of cancer crossover trial comparing single-agent paclitaxel and doxorubicin as first- and second-line treatment of advanced breast cancer.
Auteur:	Piccart-Gebhart, Martine; Bruning, Peter; Gamucci, T; Klijn, J G; Roy, J A; Awada, Ahmad; Kusenda, Zlatko; Van Vreckem, Ann; Paridaens, R.
Informations sur la publication:	Seminars in oncology, 23, 5 Suppl 11, page (11-15)
Statut de publication:	Publié, 1996-10
Sujet CREF:	Sciences bio-médicales et agricoles
MeSH keywords:	Adenocarcinoma -- drug therapy
	Adult
	Aged
	Antibiotics, Antineoplastic -- administration & dosage
	Antibiotics, Antineoplastic -- adverse effects
	Antibiotics, Antineoplastic -- therapeutic use
	Antineoplastic Agents, Phytogenic -- administration & dosage
	Antineoplastic Agents, Phytogenic -- adverse effects
	Antineoplastic Agents, Phytogenic -- therapeutic use
	Breast Neoplasms -- drug therapy
	Cross-Over Studies
	Disease Progression
	Doxorubicin -- administration & dosage
	Doxorubicin -- adverse effects
	Doxorubicin -- therapeutic use
	Europe
	Female
	Heart Failure -- chemically induced
	Humans
	Infusions, Intravenous
	Injections, Intravenous
	Middle Aged
	Neutropenia -- chemically induced
	Paclitaxel -- administration & dosage
	Paclitaxel -- adverse effects
	Paclitaxel -- therapeutic use
	Prospective Studies
	Remission Induction
Note générale:	Clinical Trial
	Comparative Study
	Journal Article
	Randomized Controlled Trial
Langue:	Anglais
Identificateurs:	urn:issn:0093-7754
	info:pmid/8893893